In the claims:

Please amend the claims as follows.

Claims 1-53 (Canceled).

Claim 54 (Amended): A fusion protein comprising an antigen of an influenza virus, or an antigenic portion thereof, and a stress protein, or a portion thereof, wherein the antigen of the influenza virus is nucleoprotein, neuraminidase, M1, M2, PB1, PB2, or PA and the fusion protein induces an immune response against the antigen in a mammal to whom the fusion protein is administered.

Claims 55-56 (Canceled).

Claim 57 (Amended): The fusion protein of claim 54, wherein the antigen of the influenza virus is [hemagglutinin,] nucleoprotein[, neuraminidase, Ml, M2, PB1, PB2, or PA].

Claim 58 (Reiterated): The fusion protein of claim 54, wherein the fusion protein is encoded by plasmid pET65MP/NP-B or plasmid pET65MP/NP-D.

Claim 59 (Reiterated): The fusion protein of claim 54, wherein the antigen includes a CTL epitope.

Claim 60 (Canceled).

Claim 61 (Amended): A fusion protein comprising an antigen of an influenza virus, or an antigenic portion thereof, and a bacterial stress protein, or a portion thereof, wherein the antigen of the influenza virus is nucleoprotein, neuraminidase, M1, M2, PB1, PB2, or PA and the fusion protein induces an immune response against the antigen in a mammal to whom the fusion protein is administered.

Claim 62 (Reiterated): The fusion protein of claim 61, wherein the bacterial stress protein is a mycobacterial stress protein.

Claim 63 (Reiterated): A composition comprising the fusion protein of claim 54 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

Claim 64 (Reiterated): A method of inducing an immune response against an antigen of an influenza virus, the method comprising administering the fusion protein of claim 54 to a vertebrate in an amount effective to induce an immune response against the antigen.

Claim 65 (Reiterated): The method of claim 64, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

Claim 66 (Reiterated): A method of inducing an immune response against an antigen of the influenza virus, the method comprising administering the fusion protein of claim 58 to a vertebrate in an amount effective to induce an immune response against the antigen.

Claim 67 (Reiterated): The method of claim 66, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

Claim 68 (Reiterated): The fusion protein of claim 54, wherein the immune response is a cell mediated immune response.

Claim 69 (Reiterated): The fusion protein of claim 68, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

Claims 70-87 (Canceled).

Claim 88 (Reiterated): The fusion protein of claim 68, wherein the cell mediated immune response is a class I-restricted T cell response.

Claim 89 (Reiterated): The fusion protein of claim 68, wherein the cell mediated immune response is a class II-restricted T cell response.

Claim 90 (Reiterated): The fusion protein of claim 59, wherein the CTL epitope is a class I-restricted T cell epitope.

Claim 91 (Reiterated): The fusion protein of claim 59, wherein the CTL epitope is a class II-restricted T cell epitope.

Claim 92 (Reiterated): The fusion protein of claim 62, wherein the stress protein is hsp65.

Claim 93 (Reiterated): The fusion protein of claim 62, wherein the stress protein is hsp71.

Claim 94 (Reiterated): The fusion protein of claim 54, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophillin, an Hsp20-30, ClpP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.

Claim 95 (Reiterated): The method of claim 64, wherein the immune response is a cell mediated immune response.

Claim 96 (Reiterated): The method of claim 95, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

Claim 97 (Reiterated): The method of claim 95, wherein the cell mediated immune response is a class I-restricted T cell response.

Claim 98 (Reiterated): The method of claim 95, wherein the cell mediated immune response is a class II-restricted T cell response.

Claims 99-124 (Canceled).